IDEAYA Biosciences Financial Statements
NASDAQ: IDYAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IDEAYA Biosciences revenue and earnings
In fiscal 2025, IDEAYA Biosciences generated $218.7 million in revenue, up 3024.4% from fiscal 2024. IDEAYA Biosciences reported a net loss of $113.7 million, compared with a loss of $274.5 million a year earlier. Operating margin was -72.8%.
Diluted earnings per share came in at -$1.28. Over the last 5 fiscal years, IDYA's revenue has grown at a 62.1% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
IDEAYA Biosciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 218.71M | 7.00M | 23.39M | 50.93M | 27.94M | 19.54M | 0 | — | — |
| Revenue growth (YoY) | +3024.43% | -70.07% | -54.08% | +82.28% | +43.01% | — | — | — | — |
| Operating Expenses | 378.02M | 333.98M | 157.81M | 113.43M | 78.21M | 54.88M | 44.27M | 36.42M | 14.44M |
| Research & Development | 314.70M | 294.67M | 129.51M | 89.54M | 58.16M | 39.70M | 34.32M | 31.75M | 12.38M |
| Operating Income | -159.31M | -326.98M | -134.43M | -62.50M | -50.27M | -35.34M | -44.27M | -36.42M | -14.44M |
| Other Income (Expense) | 45.62M | 52.50M | 21.47M | 3.85M | 506.00K | 849.00K | 2.30M | 2.07M | 2.43M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Net Income | -113.70M | -274.48M | -112.96M | -58.66M | -49.76M | -34.49M | -41.98M | -34.35M | -11.86M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 | -1.40 | -3.36 | -35.92 | -17.06 |
| EPS (Diluted) | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 | -1.40 | -3.36 | -35.92 | -17.06 |
| Shares Outstanding (Basic) | 88.49M | 81.68M | 57.52M | 41.44M | 35.25M | 24.72M | 12.50M | 956.25K | 695.37K |
| Shares Outstanding (Diluted) | 88.49M | 81.68M | 57.52M | 41.44M | 35.25M | 24.72M | 12.50M | 956.25K | 695.37K |
| EBITDA | -156.61M | -324.59M | -131.95M | -60.40M | -48.54M | -33.96M | -43.03M | -35.53M | -14.05M |
| Operating Margin | -72.84% | -4671.07% | -574.85% | -122.72% | -179.91% | -180.90% | — | — | — |
| Net Margin | -51.99% | -3921.10% | -483.05% | -115.17% | -178.10% | -176.55% | — | — | — |
This table shows 9 annual periods of IDEAYA Biosciences's income statement, from FY 2025 back to FY 2017, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow IDYA's reporting calendar. What is a income statement?